Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Pharma & Drugs
Share your love
Identification and Diagnosis of Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
LASIK and beyond: Navigating the changing landscape of refractive surgery | Ophthalmology Times
Ophthalmologists share how emerging LASIK techniques and technologies are improving outcomes and shaping the future of refractive surgery. (Image credit: AdobeStock/rohane) Refractive surgery continues to transform, with innovations in LASIK and other vision-correction procedures improving precision and patient outcomes. The…
Pediatric and strabismus care: Evolving tools, emerging therapies | Ophthalmology Times
Advances in imaging, diagnostics, and surgical techniques are transforming the detection and treatment of pediatric and strabismus disorders. (Image credit: AdobeStock/FOTO_STOCKER) Pediatric ophthalmology continues to evolve, with advances in diagnostic imaging, surgical techniques, and emerging therapies reshaping the management of…
Transformative advances in vision research: It’s the science | Ophthalmology Times
(Image Credit: AdobeStock/kkolosov) As part of Ophthalmology Times’ 50th anniversary celebration, leaders in the field are reflecting on the transformative role of science and research in advancing eye care. Deborah A. Ferrington, PhD—chief scientific officer and the Stephen J. Ryan–Arnold…
Eli Lilly to acquire Adverum Biotechnologies | Ophthalmology Times
Image credit: AdobeStock/jozefmicic The Eli Lilly and Company will acquire Adverum Biotechnologies, according to a joint press release issued by the 2 companies. The companies noted that this definitive agreement will include Adverum’s lead candidate, Ixo-vec. Adverum and Lilly’s merger…
Anti-VEGF innovations in retinal disease: From molecules to medicine | Ophthalmology Times
(Image Credit: AdobeStock) The structural differences among newer second-generation anti-VEGF agents—and their implications for clinical efficacy and treatment durability—were the focus of a recent Ophthalmology Times Case-Based Roundtable®. The discussion also highlighted real-world experiences and evidence regarding extended treatment intervals…
Regeneron receives another CRL for its Eyelea 8 mg | Ophthalmology Times
Regeneron has once again received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the company’s request for approval of its prefilled syringe option of high-dose (HD) Eylea (aflibercept) 8 mg.1 The FDA cited unresolved…
The future of glaucoma care: Where innovation meets everyday practice | Ophthalmology Times
Specialists in glaucoma care share insights on evolving strategies, technologies, and treatments shaping the future of patient management. (Image credit: AdobeStock) As glaucoma care continues to advance, ophthalmologists are embracing innovative technologies and new approaches that are reshaping diagnosis and…
New data from Sweden highlight lesion features that accelerate GA growth | Ophthalmology Times
(Image Credit: AdobeStock/Alexey Novikov) The lesion characteristics of patients with geographic atrophy (GA) were found to affect the lesion growth rate, with fovea-sparing, multifocal, and bilateral lesions having the fastest growth rates in a study published in Translational Vision Science…
Throwback Series: Managing childhood glaucoma in a resource-limited locale | Ophthalmology Times
In celebration of Ophthalmology Times’ 50th anniversary, leaders revisit a memorable “throwback” case from earlier in their careers. In this special series, they reflect on how evolving knowledge, techniques, and technologies have transformed the way such cases are managed today.…